Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Celgene: Open-label Touchstone extension study showed symptom improvement

Celgene International Sarl announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis are to be presented at the United European Gastroenterology Week in Vienna, Austria and at the American College of Gastroenterology Annual Scientific Meeting in Las Vegas. Ozanimod is an investigational selective S1P 1 and 5 receptor modulator. TOUCHSTONE evaluated the efficacy and safety of 0.5 mg and 1 mg doses of ozanimod compared with placebo after eight weeks of treatment in 197 patients with moderate to severe active ulcerative colitis. Patients who achieved a clinical response at week 8 continued with their original treatment through week 32 in a maintenance phase. The primary endpoint was the proportion of patients in remission at week 8. Secondary endpoints were: the proportion of patients achieving a clinical response, the proportion of patients with mucosal improvement and the change from baseline in Mayo score. Previously reported results showed TOUCHSTONE met its primary endpoint and secondary endpoints with statistical significance for patients on the 1 mg dose of ozanimod versus placebo. TOUCHSTONE participants in all three treatment arms entered the open-label extension if they did not respond to treatment after the induction phase, relapsed during the maintenance phase or completed the maintenance phase The objective of the open-label extension phase is to evaluate the long-term efficacy and safety of daily ozanimod 1 mg. Treatment with ozanimod 1 mg in the extension phase also showed a decrease in the proportion of patients with rectal bleeding and moderate or severe diarrhea. "Findings from this extension study at week 44 showed improvements in efficacy measures for patients who took ozanimod throughout both the blinded study and the extension," said Scott Smith, President, Celgene Inflammation & Immunology. "We recognize the strong need for innovative treatments that help patients with inflammatory bowel disease achieve durable results. We are committed to advancing additional transformational oral treatment options for these patients."

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.
10/17/16
LEER
10/17/16
NO CHANGE
LEER
Market Perform
Celgene data suggests viable drug, says Leerink
Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

FSLR

First Solar

$38.42

1.19 (3.20%)

, MNK

Mallinckrodt

$45.62

0.2527 (0.56%)

09:55
06/23/17
06/23
09:55
06/23/17
09:55
Options
Early notable gainers among liquid option names on June 23rd »

Notable gainers among…

FSLR

First Solar

$38.42

1.19 (3.20%)

MNK

Mallinckrodt

$45.62

0.2527 (0.56%)

EQT

EQT Corporation

$52.97

0.94 (1.81%)

RRC

Range Resources

$21.69

0.26 (1.21%)

CXO

Concho Resources

$115.30

1.415 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 03

    Aug

  • 05

    Sep

  • 14

    Nov

ARCC

Ares Capital

$16.24

0.06 (0.37%)

, TRI

Thomson Reuters

$46.39

0.02 (0.04%)

09:55
06/23/17
06/23
09:55
06/23/17
09:55
Conference/Events
Wells Fargo BDC industry analysts hold an analyst/industry conference call »

BDC Analyst Bock, along…

ARCC

Ares Capital

$16.24

0.06 (0.37%)

TRI

Thomson Reuters

$46.39

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 01

    Aug

DDAIF

Daimler AG

$72.82

-0.09 (-0.12%)

, PCAR

Paccar

09:50
06/23/17
06/23
09:50
06/23/17
09:50
Hot Stocks
EU commercial vehicle registrations up 9% in May »

In May, EU commercial…

DDAIF

Daimler AG

$72.82

-0.09 (-0.12%)

PCAR

Paccar

CNHI

CNH Industrial

$11.34

-0.1 (-0.87%)

NAV

Navistar

$25.37

-0.02 (-0.08%)

CMI

Cummins

$159.00

0.04 (0.03%)

ALSN

Allison Transmission

$37.25

0.06 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$59.51

-0.45 (-0.75%)

09:50
06/23/17
06/23
09:50
06/23/17
09:50
Options
Opening activity in Starbuck's expiring calls »

Opening activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

09:50
06/23/17
06/23
09:50
06/23/17
09:50
General news
Treasury Option Action: 10-year positioning »

Treasury Option Action:…

MITL

Mitel

$7.32

0.08 (1.11%)

09:49
06/23/17
06/23
09:49
06/23/17
09:49
Conference/Events
Mitel management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 29

    Aug

WHR

Whirlpool

$192.96

-2.2 (-1.13%)

09:48
06/23/17
06/23
09:48
06/23/17
09:48
Periodicals
Whirlpool refrigerator started deadly fire in Grenfell Tower, Bloomberg says »

A fire in London's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFM

Sprouts Farmers Market

$21.55

0.17 (0.80%)

09:47
06/23/17
06/23
09:47
06/23/17
09:47
Rumors
Rumor moving shares of Sprouts Farmers Market »

Rumor: Sprouts Farmers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
06/23/17
06/23
09:45
06/23/17
09:45
General news
New Home Sales to be reported at 10:00 »

May New Home Sales will…

GPMT

Granite Point Mortgage

09:44
06/23/17
06/23
09:44
06/23/17
09:44
Syndicate
Breaking Syndicate news story on Granite Point Mortgage »

Granite Point Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

GPMT

Granite Point Mortgage

09:43
06/23/17
06/23
09:43
06/23/17
09:43
Syndicate
Breaking Syndicate news story on Granite Point Mortgage »

Granite Point Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

MDSO

Medidata

$80.25

4.25 (5.59%)

09:42
06/23/17
06/23
09:42
06/23/17
09:42
Conference/Events
Medidata management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

LPI

Laredo Petroleum

09:41
06/23/17
06/23
09:41
06/23/17
09:41
Conference/Events
Laredo Petroleum management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

IFF

International Flavors

09:41
06/23/17
06/23
09:41
06/23/17
09:41
Hot Stocks
International Flavors to settle trade secret lawsuit with ZoomEssence for $56M »

ZoomEssence and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPMT

Granite Point Mortgage

09:40
06/23/17
06/23
09:40
06/23/17
09:40
Syndicate
Granite Point Mortgage indicated to open at $18-$19, IPO priced at $19.50 »

Granite Point Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

LGF.A

Lionsgate

09:40
06/23/17
06/23
09:40
06/23/17
09:40
Conference/Events
Lionsgate management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NGD

New Gold

, GILD

Gilead

$70.48

2.98 (4.41%)

09:40
06/23/17
06/23
09:40
06/23/17
09:40
Options
Unusually active option classes on open June 23rd »

Unusual total active…

NGD

New Gold

GILD

Gilead

$70.48

2.98 (4.41%)

ORCL

Oracle

VRX

Valeant

AMD

AMD

$14.38

0.4 (2.86%)

DIS

Disney

SLV

iShares Silver Trust

CAT

Caterpillar

COST

Costco

$159.79

-3.36 (-2.06%)

TWTR

Twitter

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 19

    Jul

  • 08

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

STML

Stemline

$8.50

0.15 (1.80%)

09:39
06/23/17
06/23
09:39
06/23/17
09:39
Hot Stocks
Stemline presents updated stage 1 and 2 data from SL-401 trial »

Stemline Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Sep

LGF

Use LGF.A, LGF.B

09:39
06/23/17
06/23
09:39
06/23/17
09:39
Conference/Events
Use LGF.A, LGF.B management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

INN

Summit Hotel Properties

09:38
06/23/17
06/23
09:38
06/23/17
09:38
Conference/Events
Summit Hotel Properties management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 13

    Jul

IMGN

ImmunoGen

$5.82

-0.2 (-3.32%)

09:38
06/23/17
06/23
09:38
06/23/17
09:38
Conference/Events
ImmunoGen management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

REGN

Regeneron

$526.53

4.51 (0.86%)

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Hot Stocks
Breaking Hot Stocks news story on Regeneron »

Regeneron down 4.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$14.68

0.48 (3.38%)

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Periodicals
Several private equity firms have reached out to Etsy, Dealreporter says »

While Etsy has not been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Technical Analysis
Technical View: Caterpillar slips lower, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HQY

HealthEquity

$51.05

-0.39 (-0.76%)

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Conference/Events
HealthEquity management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.